focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
It’s the same crap time and time again. Small glimmer of hope last week with some share price action on low volume.
Renewed cries of news inbound. Some real positivity around the board.
Then anti climax pull back and arguments with resident trolls.
If anyone was looking at buying into this share for the first time they might have been emboldened to do so over the weekend.
if they read the board this morning guarantee they will run a mile because you can’t just filter and ignore!
Size “ We won't be diluted if we get on STRIVE or another PT. This is key. Dilution is not envitable while these options remain.”
A funded trial like Strive does not negate the potential or requirement for dilution. It does however put us in a stronger position and the kick to the share price would make a market raise more feasible if required.
For what it’s worth I think it’s worth a punt on a quick return in the new tax year.
In and out on trial news.
Fruits - Everything you have described is still dilution it is dilution of the asset.
Until the model chosen to move forward is finalised you cannot put a number on this. You can assume it will be higher than todays price but putting a number is destined to disappoint people.
You can’t comment on a price target without knowing what has to be given away to get there.
We cannot get to a P3 without giving something in return the board will be trying to make that sacrifice as small as possible.
But throwing out price targets is mindless ramping. Given that we know we will need some form of dilution in the near future.
Developing drugs takes decades.
The pandemic significantly reduced dev cycle times primarily due to the urgency to speed up decision making and the availability of trial participants.
Now we are in a post pandemic situation you’ll notice decision making takes longer, trials are taking longer the industry has shifted down a gear.
It was a huge missed opportunity by SNG not to get approval during the ripe period but let’s face it they had an uphill struggle all the way due to their size and resources available to them.
To suggest a drug in early stages of development is in anyway a threat to SNG is ludicrous come back in 5-8years and maybe.
By then SNG will be bang or bust anyway.
Fruits - I think you misunderstood the point I was making.
As far as the company have communicated with us *there is no concrete plan yet*
Once this concrete plan is communicated the money will come and the two may be hand in hand or closely following each other.
I’m not saying they don’t have a plan behind the scenes I’m just saying that we don’t know what it is yet.
And that the money isn’t here because it’s clearly not required right this second.
To be fair Tommy Mani is right your silence surrounding the full sprinter results is quite telling.
What do you actually make of them?
Mani with regards to funding my stance is if we had £100mil today as far as the companies communications are concerned we wouldn’t know what to do with it.
So until they figure out what to do cash is not the road block.
If they figure out what to do the cash will follow.
Mani - You clearly are concerned on funding.
Personally funding is not the main issue for me.
If they sort out an attractive route to commercialisation funding will sort itself.
This later point is taking time and may never materialise. Which is why I’m on the sidelines currently.
TP - I would concur the board are genuine honest people. For some this is their life’s work and the only criticism is they may be overly detailed orientated and lack some business savy.
The real issue here is PI’s who joined the bandwagon gambling money they can’t afford to loose and now expecting regular updates.
When investors realise how insignificant they are in the big picture they might learn to sit tight and wait or move on.
Mani - You could argue they did everything they promised to do in the last raise in delivering a P3 which unfortunately narrowly missed the mark.
Until they ask for more funds I don’t see an issue with what they are doing.
And believe me if they are gearing up to ask for more funds they’d be very vocal with the market.
Observations that you may have missed.
When SNG did their first website update post P2 Prior to kick off of P3 they had a prominent advert for recruiting new research.
Soon after in Nov 2020 Pedro moved internally into a new role as Clinical Research Nurse Manager.
Off the back of this UNiVERSAL came about.
This has been about furthering research and utilising the staff they have which would no longer be contributing to the covid objective as the trials became bigger, global and US centric.